Skip to main content

Talk Bio

Search This Blog

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on July 17, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

GlaxoSmithKline (GSK) has ended development of its experimental cough drug camlipixant for refractory chronic cough after mixed Phase 3 trial data, dealing a blow to hopes that the asset could become a blockbuster therapy and a key revenue driver for the company.

Sources:

GSK axes key cough drug candidate after phase 3 data end blockbuster hopes

Pharmalittle: We're reading about rising drug shortages, GSK coughing up a trial loss, and more

GSK to halt further development of cough drug after missing main goal

GSK stops development of chronic cough drug after late-stage ...

[PDF] Q1 2026 Announcement - GSK

GSK continues to advance the future of respiratory ...

GSK axes vaccine from $2.1B deal, switches to preclinical ...

GSK stops development of chronic cough drug after late- ...

Camlipixant by GSK for Chronic Cough: Likelihood of ...

GSK Scraps Chronic Cough Drug After Mixed Trial Results

Disappointing Data Prompts GSK to Drop Cough Drug Development - GSK (NYSE:GSK)

GSK to halt further development of cough drug after missing main goal

GSK Sets Up Late-Stage Readouts: Chronic Cough Phase 3 Data ...

GSK (NYSE: GSK) halts camlipixant cough drug after Phase III data

GSK overhauls R&D, axes 30 programs to regain edge

CALM-1 CALM-2 camlipixant Chronic cough Chronic refractory cough Phase 3 Sales - occupational activity SmithKline Beecham

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC